Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282660 | 0.93 | PRMT5 (0.46) | FAAHREV1C5AR1NPC1PRMT5 | |
| SCHEMBL5776677 | 0.90 | FAAH (0.45) | FAAHREV1C5AR1PRMT5WDR77 | |
| SCHEMBL5777580 | 0.83 | FAAH (0.51) | FAAHSIGMAR1MEN1NPC1RAB9A | |
| SCHEMBL5775017 | 0.82 | FAAH (0.50) | FAAHMEN1NPC1RAB9AKMT2A | |
| SCHEMBL5778653 | 0.80 | TMEM97 (0.50) | FAAHDRD4HTR2BTMEM97SIGMAR1 | |
| SCHEMBL5775158 | 0.80 | FAAH (0.48) | FAAHMEN1NPC1RAB9AKMT2A | |
| SCHEMBL5774958 | 0.78 | FAAH (0.49) | FAAHREV1C5AR1MEN1NPC1 | |
| SCHEMBL5772604 | 0.78 | FAAH (0.52) | FAAHREV1MEN1NPC1RAB9A | |
| SCHEMBL5775449 | 0.78 | FAAH (0.46) | FAAHREV1C5AR1CHRM2HTR1A | |
| SCHEMBL11982568 | 0.76 | FAAH (0.54) | FAAHREV1C5AR1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | FAAH 23/4885REV1 1001/4885C5AR1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.